These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18364762)

  • 1. PHARMAC and cardiovascular health in New Zealand.
    Moodie P
    N Z Med J; 2008 Mar; 121(1270):102-5. PubMed ID: 18364762
    [No Abstract]   [Full Text] [Related]  

  • 2. Corporate influence over planning and presentation of clinical trials: beauty and the beast.
    Fuchs FD
    Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):7-9. PubMed ID: 20014930
    [No Abstract]   [Full Text] [Related]  

  • 3. Discontinued drugs in 2008: cardiovascular drugs.
    Zhang XS; Xiang BR
    Expert Opin Investig Drugs; 2009 Jul; 18(7):875-85. PubMed ID: 19548849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular combinations.
    Glass G
    Nat Rev Drug Discov; 2004 Sep; 3(9):731-2. PubMed ID: 15368657
    [No Abstract]   [Full Text] [Related]  

  • 5. Shaping the healthcare environment through evidence-based medicine: a case study of the ICONS project.
    Sidel J; Ryan K; Nemis-White J
    Hosp Q; 1998; 2(1):29-33. PubMed ID: 10345319
    [No Abstract]   [Full Text] [Related]  

  • 6. [The best of clinical cardiovascular pharmacology in 2005].
    Ambrosi R; Andrejak M; Drici MD; Herpin D;
    Arch Mal Coeur Vaiss; 2006 Jan; 99 Spec No 1(1):95-9. PubMed ID: 16479971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Merck Serono targets convenient, affordable medicines for patients at risk.
    Cardiovasc J Afr; 2009; 20(1):77. PubMed ID: 19287822
    [No Abstract]   [Full Text] [Related]  

  • 8. What future does the pharmaceutical industry have in the cardiovascular world?
    Braunwald E
    Eur Heart J; 2013 Apr; 34(13):943-4. PubMed ID: 23546415
    [No Abstract]   [Full Text] [Related]  

  • 9. Asian health in New Zealand--progress and challenges.
    Rasanathan K; Ameratunga S; Tse S
    N Z Med J; 2006 Oct; 119(1244):U2277. PubMed ID: 17072352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug development research: diabetes favored over cardiovascular disease?
    Suckling K
    Curr Opin Investig Drugs; 2009 Mar; 10(3):217-9. PubMed ID: 19333877
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic implications of the gender-specific aspects of cardiovascular disease.
    Regitz-Zagrosek V
    Nat Rev Drug Discov; 2006 May; 5(5):425-38. PubMed ID: 16672926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. China offers alternative gateway for experimental drugs.
    Jia H; Kling J
    Nat Biotechnol; 2006 Feb; 24(2):117-8. PubMed ID: 16465139
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cardiovascular pharmacology].
    Ravens U; Erdmann E
    Dtsch Med Wochenschr; 2004 Apr; 129(15):799. PubMed ID: 15054684
    [No Abstract]   [Full Text] [Related]  

  • 15. [Methods of evaluating drug therapy, particularly in cardiovascular diseases].
    Lövy O; Toman J
    Cesk Zdrav; 1984 Sep; 32(8-9):361-5. PubMed ID: 6509673
    [No Abstract]   [Full Text] [Related]  

  • 16. Promises kept and broken: new pharmaceuticals.
    Malik P
    Can J Cardiol; 2002 May; 18(5):493-4. PubMed ID: 12032574
    [No Abstract]   [Full Text] [Related]  

  • 17. [The efficacy and safety of the drug treatment of cardiovascular diseases].
    Mazur NA
    Ter Arkh; 1993; 65(8):4-7. PubMed ID: 8211800
    [No Abstract]   [Full Text] [Related]  

  • 18. Can China bring its own pipeline to the market?
    Louët S
    Nat Biotechnol; 2004 Dec; 22(12):1497-9. PubMed ID: 15583646
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular risk profile assessment and medication control should come first.
    Zoccali C; Mallamaci F; Tripepi G
    Semin Dial; 2007; 20(5):405-8. PubMed ID: 17897245
    [No Abstract]   [Full Text] [Related]  

  • 20. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.